Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses.

To elucidate the role of leukotrienes (LT) in allergic asthma in humans the effect of MK-886, an LT biosynthesis inhibitor, was evaluated on antigen-induced early (EAR) and late (LAR) asthmatic reactions and bronchial responsiveness to histamine. Eight atopic men participated in a two-part, double-blind, placebo-controlled, crossover trial. MK-886 was administered in two oral doses of 500 mg and 250 mg, 1 h before and 2 h after allergen inhalation, respectively. Biochemical effects of MK-886 were evaluated by the inhibition of urinary LTE4 excretion and calcium ionophore-stimulated LTB4 biosynthesis in whole blood ex vivo. MK-886 significantly inhibited the EAR by 58.4% (AUC0-3 h) and the LAR by 43.6% (AUC3-7 h) when compared with placebo (p < 0.01). There was no difference in PC20 histamine 30 h post allergen challenge between MK-886 and placebo (0.33 and 0.27 doubling doses, p > 0.1). MK-886 inhibited calcium ionophore-stimulated LTB4 production in whole blood (54.2 +/- 25.6%) for up to 6 h post allergen challenge. LTE4 excretion in urine was inhibited by 51.5% during the EAR by as much as 80% during the LAR. This indicates that LT play a role in allergen-induced asthmatic reactions in humans in vivo and that LT synthesis inhibitors such as MK-886 should be further explored for the treatment of asthma.

[1]  D. Margolskee,et al.  Leukotriene (LT) D4 Is Involved in Antigen‐Induced Asthma: a Study with the LTD4 Receptor Antagonist, MK‐571 , 1991, Annals of the New York Academy of Sciences.

[2]  C. Dollery,et al.  Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects , 1991, The Lancet.

[3]  Paul H. Rubin,et al.  Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. , 1991, Thorax.

[4]  B. Matuszewski,et al.  Determination of (3-[1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel leukotriene biosynthesis inhibito , 1991 .

[5]  S. Spector,et al.  677 The therapeutic effects of MK-571, a potent and selective leukotriene (LT) D4 receptor antagonist, in patients with chronic asthma , 1991 .

[6]  H. Knapp,et al.  Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. , 1990, The New England journal of medicine.

[7]  P. O'Byrne,et al.  Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. , 1990, The New England journal of medicine.

[8]  Paul H. Rubin,et al.  The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. , 1990, The New England journal of medicine.

[9]  N. Voelkel,et al.  Leukotriene E4 elimination and metabolism in normal human subjects. , 1990, The Journal of biological chemistry.

[10]  P. O'Byrne,et al.  Urinary leukotriene E4 levels during early and late asthmatic responses. , 1990, The Journal of allergy and clinical immunology.

[11]  P. Sterk,et al.  The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. , 1990, The Journal of allergy and clinical immunology.

[12]  J. Cooper,et al.  Leukotriene B4 increases pulmonary transvascular filtration by a neutrophil-independent mechanism. , 1990, Journal of applied physiology.

[13]  H E Morton,et al.  MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. , 1990, The Journal of biological chemistry.

[14]  R. Dixon,et al.  Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis , 1990, Nature.

[15]  S. Charleson,et al.  Comparison of urinary leukotriene E4 and 16-carboxytetranordihydro leukotriene E4 excretion in allergic asthmatics after inhaled antigen. , 1990, Eicosanoids.

[16]  E. Chi,et al.  Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability. , 1989, The Journal of clinical investigation.

[17]  D. Denis,et al.  L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. , 1989, Canadian journal of physiology and pharmacology.

[18]  C. Dollery,et al.  URINARY LEUKOTRIENE E4 AFTER ANTIGEN CHALLENGE AND IN ACUTE ASTHMA AND ALLERGIC RHINITIS , 1989, The Lancet.

[19]  S. Charleson,et al.  Measurement of urinary leukotrienes by reversed-phase liquid chromatography and radioimmunoassay. , 1989, Clinical chemistry.

[20]  M. Chan-yeung,et al.  Release of leukotrienes in patients with bronchial asthma. , 1988, The Journal of allergy and clinical immunology.

[21]  D. Cockcroft,et al.  Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. , 2015, The American review of respiratory disease.

[22]  P. O'Byrne,et al.  Late asthmatic responses. , 1987, The American review of respiratory disease.

[23]  Cockcroft Dw.  Bronchial inhalation tests. II. Measurement of allergic (and occupational) bronchial responsiveness. , 1987 .

[24]  S. Holgate,et al.  The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5' monophosphate in atopic asthma. , 1987, The American review of respiratory disease.

[25]  F. Carey,et al.  Radioimmunoassay of LTB4 and 6-trans LTB4: analytical and pharmacological characterisation of immunoreactive LTB4 in ionophore stimulated human blood. , 1986, Prostaglandins, leukotrienes, and medicine.

[26]  H. Sluiter,et al.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.

[27]  T. Sorrell,et al.  Quantitation of sulfidopeptide leukotrienes by reversed-phase high-performance liquid chromatography. , 1985, Journal of chromatography.

[28]  S. Dahlén,et al.  Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. , 1983, Proceedings of the National Academy of Sciences of the United States of America.